|4Mar 12, 6:04 PM ET

Berger Dietmar 4

4 · GILEAD SCIENCES, INC. · Filed Mar 12, 2025

Insider Transaction Report

Form 4
Period: 2025-03-10
Berger Dietmar
Chief Medical Officer
Transactions
  • Award

    Restricted Stock Unit

    2025-03-10+8,53057,505 total
    Common Stock (8,530 underlying)
  • Award

    Non-qualified Stock Option (Right to Buy)

    2025-03-10+37,71037,710 total
    Exercise: $117.21Exp: 2035-03-10Common Stock (37,710 underlying)
Footnotes (3)
  • [F1]Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
  • [F2]The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.
  • [F3]The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT